8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 15, 2026·SEC
Material company update
May 6, 2026·SEC
Anavex Life Sciences Corp.(AVXL)Earnings, Financials & Key Ratios
AVXL•NASDAQ
Price updated Jun 19, 2026
AboutAnavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$46M-7.8%
- Net Income-$46M-7.8%
- EPS (Diluted)-0.54-3.8%
- ROE-43.11%-31.4%
AVXL Key Insights
Anavex Life Sciences Corp. (AVXL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 12.0% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 11 (bottom 11%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AVXL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AVXL Price & Volume
Anavex Life Sciences Corp. (AVXL) stock price & volume — 10-year historical chart
Loading chart...
AVXL Growth Metrics
Anavex Life Sciences Corp. (AVXL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.08%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.67%
Return on Capital
10 Years-41.86%
5 Years-41.86%
3 Years-42.45%
Last Year-47.79%
AVXL Recent Earnings
Anavex Life Sciences Corp. (AVXL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q3 2026Latest
Jun 16, 2026Metric
Actual
Est
EPS
$0.07+0.0%
$0.07
Rev
—
—
Q3 2026
Jun 9, 2026Metric
Actual
Est
EPS
$0.07+0.0%
$0.07
Rev
—
—
Q3 2026
Jun 2, 2026Metric
Actual
Est
EPS
$0.07+0.0%
$0.07
Rev
—
—
Q1 2026
Feb 9, 2026Metric
Actual
Est
EPS
$0.06+40.0%
$0.10
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 16, 2026 | $0.07vs $0.07+0.0% | — |
| Q3 2026 | Jun 9, 2026 | $0.07vs $0.07+0.0% | — |
| Q3 2026 | Jun 2, 2026 | $0.07vs $0.07+0.0% | — |
| Q1 2026 | Feb 9, 2026 | $0.06vs $0.10+40.0% | — |
Based on last 12 quarters of dataView full earnings history →
AVXL Peer Comparison
Anavex Life Sciences Corp. (AVXL) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SAVA | 63.77M | 1.32 | -2.54 | -95.77% | ||||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 ATNM | 32.32M | 1.03 | -0.95 | -260.79% | -218.67% | 0.22 | ||
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare AVXL vs Peers
Anavex Life Sciences Corp. (AVXL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AVXL Income Statement
Anavex Life Sciences Corp. (AVXL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | 15.54M | 19.18M | 28.81M | 30.94M | 42M | 50.99M | 55.76M | 52.88M | 51.41M | 44.6M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 5.01M | 5.99M | 6.85M | 5.86M | 9.02M | 13.07M | 12.05M | 11.04M | 13.82M | 12.8M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 10.67M | 13.34M | 22.26M | 25.23M | 32.98M | 37.92M | 43.72M | 41.84M | 37.59M | 31.8M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 2.02M | 1.63M | 2.47M | 4.38M | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -42M▲ 0% | -50.99M▼ 21.4% | -55.76M▼ 9.4% | -52.88M▲ 5.2% | -51.41M▲ 2.8% | -44.6M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | - | - | - | - | -21.39% | -9.37% | 5.18% | 2.78% | - |
EBITDA | -15.57M | -19.13M | -28.88M | -31.06M | -37.64M | -47.62M | -46.54M | -43M | -46.38M | -38.87M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -3.51% | -22.92% | -50.94% | -7.56% | -21.17% | -26.51% | 2.27% | 7.6% | -7.85% | 24.6% |
D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBIT | 0 | 0 | 0 | 0 | -37.64M | -47.62M | -46.54M | -43M | -46.38M | -38.87M |
Net Interest Income | 0 | 0 | 0 | 0 | 26K | 947K | 5.55M | 7.32M | 4.68M | 4.36M |
Interest Income | 88.1K | 255.09K | 207.28K | 179.97K | 26K | 947K | 6.52M | 7.32M | 4.68M | 4.36M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 964K | 0 | 0 | 0 |
Other Income/Expense | 2.05M | 1.58M | 2.54M | 4.5M | 4.36M | 3.37M | 8.26M | 9.88M | 5.03M | 4.67M |
Pretax Income | -13.4M▲ 0% | -17.38M▼ 29.7% | -26.21M▼ 50.8% | -26.26M▼ 0.2% | -37.64M▼ 43.4% | -47.62M▼ 26.5% | -47.51M▲ 0.2% | -43M▲ 9.5% | -46.38M▼ 7.8% | -39.93M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 59.61K | 72.75K | 82.18K | 22.66K | 268K | 358K | 0 | 0 | 0 | 18K |
Effective Tax Rate % | -0.44% | -0.42% | -0.31% | -0.09% | -0.71% | -0.75% | 0% | 0% | 0% | -0.05% |
Net Income | -13.46M▲ 0% | -17.45M▼ 29.7% | -26.29M▼ 50.7% | -26.28M▲ 0.1% | -37.91M▼ 44.2% | -47.98M▼ 26.6% | -47.51M▲ 1.0% | -43M▲ 9.5% | -46.38M▼ 7.8% | -39.95M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | 8.66% | -29.66% | -50.66% | 0.06% | -44.25% | -26.56% | 0.99% | 9.48% | -7.85% | 14.08% |
Net Income (Continuing) | 0 | 0 | 0 | 0 | -37.91M | -47.98M | -47.51M | -43M | -46.38M | -39.95M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.33▲ 0% | -0.39▼ 18.2% | -0.54▼ 38.5% | -0.45▲ 16.7% | -0.54▼ 20.0% | -0.62▼ 14.8% | -0.60▲ 3.2% | -0.52▲ 13.3% | -0.54▼ 3.8% | -0.45▲ 0% |
EPS Growth % | 21.43% | -18.18% | -38.46% | 16.67% | -20% | -14.81% | 3.23% | 13.33% | -3.85% | 15.67% |
EPS (Basic) | -0.33 | -0.39 | -0.54 | -0.45 | -0.54 | -0.62 | -0.60 | -0.52 | -0.54 | - |
Diluted Shares Outstanding | 40.84M | 44.66M | 48.91M | 58.2M | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M | 89.03M |
Basic Shares Outstanding | 40.84M | 44.66M | 48.91M | 58.2M | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M | 89.03M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AVXL Balance Sheet
Anavex Life Sciences Corp. (AVXL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 27.79M | 24.32M | 25.33M | 34.54M | 161.62M | 152.7M | 154.39M | 135.57M | 103.81M | 132.99M |
Cash & Short-Term Investments | 27.44M | 22.93M | 22.19M | 29.25M | 152.11M | 149.16M | 151.02M | 132.19M | 102.58M | 131.75M |
Cash Only | 27.44M | 22.93M | 22.19M | 29.25M | 152.11M | 149.16M | 151.02M | 132.19M | 102.58M | 131.75M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 9.75K | 1.87M | 2.64M | 4.85M | 9.14M | 3.19M | 2.71M | 2.45M | 809K | 844K |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | -2.64M | 0 | 16.36K | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 2.64M | 0 | -16.36K | 162 | 653K | 931K | 429K | 396K |
Total Non-Current Assets | 52.4K | 52.4K | 0 | 5.29M | 16.36K | 3.55B | 3.36M | 0 | 0 | 0 |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 52.4K | 52.4K | 0 | 5.29M | 16.36K | 3.55B | 3.36M | 0 | 0 | 0 |
Total Assets | 27.84M▲ 0% | 24.38M▼ 12.4% | 25.33M▲ 3.9% | 34.54M▲ 36.4% | 161.62M▲ 367.9% | 152.7M▼ 5.5% | 154.39M▲ 1.1% | 135.57M▼ 12.2% | 103.81M▼ 23.4% | 132.99M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | 193.08% | -12.44% | 3.91% | 36.37% | 367.88% | -5.51% | 1.1% | -12.19% | -23.42% | -62.91% |
Total Current Liabilities | 3.58M | 3.88M | 5.04M | 7.31M | 10.8M | 10.21M | 12.53M | 15.3M | 8.95M | 6.37M |
Accounts Payable | 3.58M | 2.96M | 3.52M | 3.99M | 4.74M | 3.82M | 4.32M | 9.63M | 4.25M | 2.64M |
Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 443.83K | 443.83K | 917K | 842K | 805K | 3.24M |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | -47 | 1.36M | 1.53M | 1.56M | 1.7M |
Current Ratio | 7.75x | 6.26x | 5.03x | 4.73x | 14.97x | 14.95x | 12.32x | 8.86x | 11.60x | 20.87x |
Quick Ratio | 7.75x | 6.26x | 5.55x | 4.73x | 14.97x | 14.95x | 12.32x | 8.86x | 11.60x | 20.87x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3.58M | 3.88M | 5.04M | 7.31M | 10.8M | 10.21M | 12.53M | 15.3M | 8.95M | 6.37M |
Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net Debt | -27.44M | -22.93M | -22.19M | -29.25M | -152.11M | -149.16M | -151.02M | -132.19M | -102.58M | -131.75M |
Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 3.39x |
Interest Coverage | - | - | - | - | - | - | -48.28x | - | - | - |
Total Equity | 24.25M▲ 0% | 20.49M▼ 15.5% | 20.29M▼ 1.0% | 27.24M▲ 34.2% | 150.82M▲ 453.7% | 142.49M▼ 5.5% | 141.85M▼ 0.4% | 120.26M▼ 15.2% | 94.87M▼ 21.1% | 126.62M▲ 0% |
Equity Growth % | 284.49% | -15.51% | -0.98% | 34.24% | 453.73% | -5.52% | -0.45% | -15.22% | -21.12% | -63.08% |
Book Value per Share | 0.59 | 0.46 | 0.41 | 0.47 | 2.16 | 1.85 | 1.78 | 1.44 | 1.11 | 1.42 |
Total Shareholders' Equity | 24.25M | 20.49M | 20.29M | 27.24M | 150.82M | 142.49M | 141.85M | 120.26M | 94.87M | 126.62M |
Common Stock | 43.33K | 45.94K | 52.65K | 62.05K | 75.92K | 77.94K | 82K | 85K | 87K | 93K |
Retained Earnings | -91.48M | -108.93M | -133.4M | -159.68M | -197.59M | -245.56M | -293.07M | -336.07M | -382.45M | -388.13M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AVXL Cash Flow Statement
Anavex Life Sciences Corp. (AVXL) cash flow — operating, investing & free cash flow history
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.02M | -12.58M | -18.53M | -21.29M | -30.38M | -24.24M | -27.79M | -30.81M | -39.04M | -34.08M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | 2.38% | -39.54% | -47.25% | -14.9% | -42.73% | 20.23% | -14.63% | -10.89% | -26.72% | -79.09% |
Net Income | -13.46M | -17.25M | -26.29M | -26.28M | -37.91M | -47.98M | -47.51M | -43M | -46.38M | -39.95M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 4.14M | 5.52M | 6.43M | 4.88M | 8.23M | 18.38M | 16.37M | 9.44M | 11.55M | 10.6M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -75.2K | 0 | 35.38K | 0 | 0 | 0 | 845K | 0 | 0 | 0 |
Working Capital Changes | 382.81K | -846.67K | 1.3M | 116.52K | -706K | 5.36M | 2.5M | 2.75M | -4.22M | -4.73M |
Change in Receivables | 54.44K | -231.1K | -772.39K | -2.21M | -4.29M | 5.94M | 484K | 260K | 1.64M | 1.71M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 38.23K | 683.8K | 465.72K | 751K | -914K | 497K | 5.3M | -5.38M | -1.93M |
Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 27.27M | 8.07M | 17.78M | 28.35M | 153.24M | 21.29M | 29.65M | 11.97M | 9.43M | 45.05M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 27.27M | 8.17M | 17.83M | 28.75M | 153.22M | 22M | 29.65M | 11.97M | 12.14M | 47.76M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | -101.13K | -50K | -403.76K | 24K | -707K | 29.65M | 11.97M | -2.71M | -1.85M |
Net Change in Cash | 18.25M▲ 0% | -4.51M▼ 124.7% | -745.01K▲ 83.5% | 7.06M▲ 1048.1% | 122.86M▲ 1639.4% | -2.95M▼ 102.4% | 1.87M▲ 163.3% | -18.84M▼ 1109.5% | -29.61M▼ 57.2% | 10.97M▲ 0% |
Free Cash Flow | -9.02M▲ 0% | -12.58M▼ 39.5% | -18.53M▼ 47.2% | -21.29M▼ 14.9% | -30.38M▼ 42.7% | -24.24M▲ 20.2% | -27.79M▼ 14.6% | -30.81M▼ 10.9% | -39.04M▼ 26.7% | -34.08M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | 2.38% | -39.54% | -47.25% | -14.9% | -42.73% | 20.23% | -14.63% | -10.89% | -26.72% | 4.32% |
FCF per Share | -0.22 | -0.28 | -0.38 | -0.37 | -0.44 | -0.32 | -0.35 | -0.37 | -0.46 | -0.38 |
FCF Conversion (FCF/Net Income) | 0.67x | 0.72x | 0.70x | 0.81x | 0.80x | 0.51x | 0.58x | 0.72x | 0.84x | 0.85x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 22.66K | 140K | 327K | 136K | 300K | 125K | 123K |
AVXL Key Ratios
Anavex Life Sciences Corp. (AVXL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -88.09% | -78.01% | -128.96% | -110.59% | -42.58% | -32.71% | -33.41% | -32.81% | -43.11% | -38.76% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | 342.55% |
Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
Interest Coverage | - | - | - | - | - | - | -48.28x | - | - | - |
FCF Conversion | 0.67x | 0.72x | 0.70x | 0.81x | 0.80x | 0.51x | 0.58x | 0.72x | 0.84x | 0.85x |
Related:AVXL Dividend History·AVXL Revenue History·AVXL Price History·AVXL P/E History·AVXL Financial Ratios·AVXL Institutional Holders
AVXL SEC Filings & Documents
Anavex Life Sciences Corp. (AVXL) SEC filings — annual & quarterly reports (10-K, 10-Q)
AVXL Frequently Asked Questions
Anavex Life Sciences Corp. (AVXL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Anavex Life Sciences Corp. (AVXL) grew revenue by 0.0% over the past year. Growth has been modest.
Anavex Life Sciences Corp. (AVXL) reported a net loss of $39.9M for fiscal year 2025.
Dividend & Returns
Anavex Life Sciences Corp. (AVXL) has a return on equity (ROE) of -43.1%. Negative ROE indicates the company is unprofitable.
Anavex Life Sciences Corp. (AVXL) had negative free cash flow of $34.1M in fiscal year 2025, likely due to heavy capital investments.